MD Anderson Cancer Center and the Broad Institute of MIT and Harvard have established a translational research platform to study rare cancers and develop a first-of-its-kind resource for the scientific community.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
